Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.

about

The human cytomegalovirus lytic cycle is induced by 1,25-dihydroxyvitamin D3 in peripheral blood monocytes and in the THP-1 monocytic cell line Beyond mineral metabolism, the bright immunomodulatory effect of vitamin D in renal disease.

P2860

Q35893959-5FA978FC-AE25-4F3C-A885-2C25D1840DBD Q54845414-020F48F6-FDA8-4250-9D8A-438E3527F990

P2860

Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.

Item

http://www.wikidata.org/entity/Q38115994

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.

@en

type

Item

label

Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.

@en

prefLabel

Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.

@en

P1476

Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.

@en

P2093

Can-Fei Zhang

http://www.w3.org/2001/XMLSchema#string

Ren-Zhong Wan

http://www.w3.org/2001/XMLSchema#string

Zhao-Peng Liu

http://www.w3.org/2001/XMLSchema#string

P2860

The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand

2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation, and crystal structure

Structure–function study of gemini derivatives with two different side chains at C-20, Gemini-0072 and Gemini-0097

Calcitriol derivatives with two different side-chains at C-20. Part 4: further chain modifications that alter VDR-dependent monocytic differentiation potency in human leukemia cells.

Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl

A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation.

Vitamin D and cancer mortality: systematic review of prospective epidemiological studies.

Removal of the 26-methyl group from 19-nor-1α,25-dihydroxyvitamin D₃ markedly reduces in vivo calcemic activity without altering in vitro VDR binding, HL-60 cell differentiation, and transcription.

A 20S combined with a 22R configuration markedly increases both in vivo and in vitro biological activity of 1α,25-dihydroxy-22-methyl-2-methylene-19-norvitamin D3

Removal of the 20-methyl group from 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD) selectively eliminates bone calcium mobilization activity.

P304

1249-1260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CMDC.201300160

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

240309886

http://www.w3.org/2001/XMLSchema#string

P698

23788554

http://www.w3.org/2001/XMLSchema#string

Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.

about

P2860

P2860

Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698